

# Supplemental Figure 1

	EGFR mutation	induction afatinib (2 months)	concurrent chemoradiation	surgery	consolidation afatinib (planned course 2 years)	pattern of first recurrence
		start (mg) stop (mg)	#chemo cycles RT dose (Gy)	procedure ypn	start (mg) stop (mg) time on afatinib (months) reason for stopping	
Patient 1	del 19	40	4 63.0		40 24	CNS only
Patient 2	del 19	40	4 72.0		40 → 30 24	CNS only
Patient 3	L858R	40 → 30	4 66.6		30 2 toxicity	distant metastases (non-CNS)
Patient 4	del 19	40	2 54.0	LUL lobectomy (lingula sparing) 0	40 22	CNS only
Patient 5	del 19	40	2 45.0	RUL sleeve lobectomy + RLL wedge (small 2nd primary) 0	30 → 20 21	no known recurrence
Patient 6	del 19	40				CNS only
Patient 7	L858R	40	2 54.0	extended RUL lobectomy 0		no known recurrence
Patient 8	del 19	40 → 30	3 70.2		30 → 20 12 progression	locoregional recurrence only
Patient 9	del 19	40 → 30	2 66.0	LLL lobectomy 1	30 <1 toxicity	distant metastases (non-CNS)
Patient 10	L858R	40	1 54.0	RUL lobectomy + RLL wedge (organizing pna) 2		no known recurrence
Patient 11	del 19	40	2 45.0	RUL lobectomy 0		no known recurrence
Patient 12	del 19	40 → 30	2 54.0	RML and RLL lobectomies 1	20 7 toxicity	CNS and distant metastases
Patient 13	L858R	40 → 30	2 63.0			CNS only
Patient 14	L858R	40	2 54.0	extended RUL lobectomy *	30 22	CNS only
Patient 15	L858R	40 → 30	2 45.0	extended RUL lobectomy 2	30 → 20 24	distant metastases (non-CNS)
Patient 16	del 19	40				local and distant progression
Patient 17	exon 18 delE709_T710insD	40	2 63.0		30 8 toxicity	distant metastases (non-CNS)
Patient 18	del 19	40	2 66.0		30 24	CNS and distant metastases
Patient 19	L858R	40 → 30	2 45.0	RML lobectomy 0	30 <1 toxicity	CNS and distant metastases

\*unable to determine, no lymph nodes identified on dissection